Chiusura precedente | 9,53 |
Aperto | 9,52 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 9,52 - 9,52 |
Intervallo di 52 settimane | 6,15 - 13,83 |
Volume | |
Media Volume | 1.302 |
Capitalizzazione | 1,083M |
Beta (5 anni mensile) | 0,15 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,62 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Ad hoc announcement pursuant to Art. 53 LR Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for AGAMREE® (vamorolone) for the treatment Duchenne muscular dystrophy (DMD) in children and adults aged 4 years and olderEuropean Commission (EC) decision on marketing authorization is expected in late 2023AGAMREE could become the first drug fully approved by the European Medicines Agency (EMA) for the treatment of patients with DMD Anticipation of vamorolone approval in the
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 3.9 million (H1-2022: CHF 6.3 million)Operating result of CHF -20.3 million (H1-2022: CHF -25.5 million) and net result of CHF -23.3 million (H1-2022: CHF -29.7 million)Review of vamorolone's regulatory filings (NDA, MAA) for Duchenne muscular dystrophy (DMD) treatment proceeding as planned
Ad hoc announcement pursuant to Art. 53 LR Chiesi Group acquires entire idebenone business including Raxone in Leber's hereditary optic neuropathy (LHON)Chiesi Group assumes French reimbursement liability of EUR 25.3 million from SantheraSanthera retains contingent value for LHON in U.S. and/or other indications worldwideSanthera ceases all Raxone-related activities and intensifies commercial preparation for Duchenne muscular dystrophy candidate vamorolone in Europe Pratteln, Switzerland, July 3